BioSante rallies 21% on drug study
Market Watch Mon, 27 Feb 2012 10:01 AM PST
BOSTON (MarketWatch) -- BioSante Pharmaceuticals shares shot up 21% to 86 cents on Monday after the company reported promising Phase I results for its GVAX vaccine for the treatment of pancreatic cancer. The shares are up 72% for the year, in part due to the recent U.S. approval of its male testosterone-replacement product Bio-T-Gel. Market Pulse Stories are Rapid-fire, short news bursts on ... |
Leave a comment
Fergus Falls Journal Mon, 27 Feb 2012 09:51 AM PST
Gloria J. Lee, who has been cancer-free for 11 years, will be the featured speaker at the Monday, March 5 “Pretty in Pink†night at Lake Region Healthcare’s Cancer Care and Research Center. The event begins at 6:30 p.m. at the center. |
Trial begins for woman accused of faking cancer
CBS 6 Richmond Mon, 27 Feb 2012 09:46 AM PST
HANOVER COUNTY, Va. (WTVR) - The trial for the woman accused of claiming she had cancer in order to raise money was scheduled to start in a Hanover County courtroom Monday. Martha Nicholas is charged with obtaining money under false pretenses. |
Victim Speaks Out
Voice of the Common Man Mon, 27 Feb 2012 09:44 AM PST
One of the women involved in a lawsuit against Eastern Health after they were misdiagnosed with breast cancer and underwent mastectomies, fails to see the logic in why the health authority refuses to send her tissue slides out of the province for examination. |
Dendreon falls on 1Q Provenge forecast
The Wenatchee World Mon, 27 Feb 2012 09:42 AM PST
SEATTLE (AP) â€" Shares of Dendreon Corp. tumbled Monday after the company forecast disappointing first-quarter sales of its prostate cancer therapy Provenge. Dendreon reported its fourth-quarter results Monday, saying it earned $38.1 million, or 26 cents per share, in the December quarter. In the fourth quarter of 2010 it lost $91.8 million, or 64 cents per share. Revenue climbed to $202.1 ... |
Dendreon plunges 18% on sales report
Market Watch Mon, 27 Feb 2012 09:31 AM PST
BOSTON (MarketWatch) -- Shares of Dendreon Corp. plunged 18% to $12.12 on Monday after it issued a weaker-than-expected quarterly sales report for its prostate cancer therapy Provenge. Dendreon shares have been on a roll since early January, when the stock soared almost 50% on stronger-than-expected sales for the therapy. Despite Monday's plunge, Dendreon's shares are still up nearly 60% for the ... |
| |
|